Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia.
Shun ItoMasahiro BannoYuji OkazakiPublished in: Infectious diseases and therapy (2022)